Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Wisner Baum Calls for Stronger Barriers Between the EPA and the Chemical Industry


News provided by

Wisner Baum

Sep 14, 2026, 08:49 ET

Share this article

Share toX

Share this article

Share toX

The revolving door between the EPA and chemical manufacturers has persisted for decades, across administrations of both parties. Wisner Baum is calling for tighter limits on personnel moves, industry access and corporate-funded science that skew chemical regulation.

LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- The EPA cannot credibly protect the public from dangerous chemicals when its officials keep moving between the agency and the industries it regulates, according to Wisner Baum LLP.

Continue Reading
“Until the government closes the revolving door and independently verifies the science placed before regulators, the public has every reason to question whether chemical-safety decisions are protecting health or protecting markets.” - Michael Baum, attorney and senior partner at Wisner Baum
“Until the government closes the revolving door and independently verifies the science placed before regulators, the public has every reason to question whether chemical-safety decisions are protecting health or protecting markets.” - Michael Baum, attorney and senior partner at Wisner Baum

"The question is not whether someone with industry experience understands chemical regulation," said Michael Baum, attorney and senior partner at Wisner Baum. "The question is whether the public can trust decisions made by officials who recently represented or worked for the companies that benefit from those decisions. The EPA must answer to the people exposed to these chemicals, not the industries selling them."

A Revolving Door Spanning Administrations

Chemical-company executives, attorneys and lobbyists move into senior regulatory posts, while former EPA officials go on to work for manufacturers, consulting firms and trade associations that lobby the agency. The pattern has held under both Republican and Democratic administrations, which is why Wisner Baum considers regulatory capture a structural problem rather than a partisan one.1

Research reviewed by Wisner Baum found that seven of the nine directors of the EPA's Office of Pesticide Programs who did not retire immediately after their tenure went on to work for the pesticide industry, including at Monsanto, DuPont and Scotts Miracle-Gro.1

In March 2026, Sens. Adam Schiff and Jeff Merkley urged four EPA chemical-safety officials to extend their recusals indefinitely and avoid communications with former employers and clients.2

The senators pointed to records showing EPA appointees met with representatives of at least 50 chemical and pesticide companies or industry associations between February and May 2025 — while their disclosed calendars showed no meetings with public-health or environmental organizations.2

"Access shapes outcomes," Baum said. "When industry representatives have a seat at the table while independent scientists, exposed communities, and public-health advocates do not, the regulatory process becomes structurally skewed before a final decision is ever announced."

Those officials had previous ties to the American Chemistry Council, the American Soybean Association, Syngenta and Scotts Miracle-Gro. The senators argued that standard recusal periods aren't long enough to keep former employers and clients from benefiting from EPA decisions.2

Industry-Funded Science Compounds the Problem

The same revolving door shapes the scientific record regulators rely on. Manufacturers frequently fund or supply the studies that support their products' safety, and that evidence can end up in EPA risk assessments and registration decisions — which manufacturers then cite as independent confirmation, even though the underlying research originated with the company.3

"The revolving door and industry-funded science reinforce each other," Baum said. "The company helps create the evidence, people with industry ties help determine how much weight that evidence receives, and the resulting approval is presented to the public as an independent government judgment."

Wisner Baum's Roundup litigation illustrates how that dynamic plays out in practice. Internal Monsanto documents produced in that litigation revealed the company's involvement in scientific publications, its efforts to discredit independent researchers, and its communications with EPA officials.4

The pattern goes back to Roundup's original approval. Fraudulent animal studies conducted at Industrial Bio-Test Laboratories helped support that approval, and the toxicologist who ran them, Paul Wright, was later convicted of fraud and served prison time after Monsanto paid for his defense.5

A widely cited 2000 study funded by Monsanto that supported Roundup's safety was retracted in 2025, after years of concern about undisclosed company involvement, questions about the study authors' independence, and reliance on Monsanto-generated data.6

After the International Agency for Research on Cancer (IARC) classified glyphosate, Roundup's active ingredient, as a probable human carcinogen in 2015, internal Monsanto documents describe two strategies the company pursued to counter that finding: ghostwriting an expert review disputing IARC's conclusion, and lobbying Congress to cut IARC's funding.4

At the same time, EPA scientists and an EPA-convened scientific advisory panel raised concerns about the agency's application of its carcinogen-risk guidelines.8 Separately, an internal Monsanto email reported that EPA official Jess Rowland contacted the federal Agency for Toxic Substances and Disease Registry (ATSDR) about its planned glyphosate review and said, as relayed by Monsanto official Dan Jenkins, "If I can kill this I should get a medal." The available email supports the claim about the separate ATSDR review; it does not, by itself, establish that Rowland blocked EPA scientists from issuing their own findings.7

"The Monsanto Papers showed how chemical-industry influence can shape both the scientific record and regulatory decision-making in the United States," Baum said. "From fraudulent animal studies at Industrial Bio-Test Laboratories and Monsanto-linked ghostwriting of scientific reviews, to Monsanto's communications with EPA official Jess Rowland, who was described in the documents as helping to block or delay an agency review, the documents revealed years of back-door machinations. The consequences did not stop at EPA. The Ninth Circuit later rejected EPA's glyphosate cancer analysis and ordered the agency to revisit it, illustrating how compromised or improperly conducted regulatory reviews can reverberate through federal policy and the courts."

On June 17, 2022, the Ninth Circuit vacated the human-health portion of EPA's glyphosate interim registration review decision and remanded it for further analysis and explanation, holding that EPA's "not likely to be carcinogenic" determination was not supported by substantial evidence and was inconsistent with parts of the agency's analysis and its own carcinogen-risk guidelines.8 EPA states that it is still updating its evaluation in response to the decision.9 On June 25, 2026, the U.S. Supreme Court held in Monsanto v. Durnell that federal pesticide law preempts state-law failure-to-warn claims that would require a cancer warning different from the label approved by EPA.10 Wisner Baum maintains that the ruling gives added urgency to an independent, scientifically sound EPA reassessment.

Wisner Baum's Call for Reform

Wisner Baum has long called for permanent or substantially longer recusal periods for officials with chemical-industry ties, full disclosure of communications with regulated companies, balanced access for independent scientists and public-health organizations, and independent review of safety decisions that rely heavily on manufacturer-funded evidence.

"The public should not need cancer victims, subpoenas, and years of litigation to discover that supposedly independent science was shaped behind the scenes," Baum said.

The firm is also calling on Congress to increase funding for independent toxicology research and to require public access to the data manufacturers submit for pesticide registrations and chemical approvals.

"EPA ethics rules should prevent conflicts, not simply manage their appearance," Baum said. "Until the government closes the revolving door and independently verifies the science placed before regulators, the public has every reason to question whether chemical-safety decisions are protecting health or protecting markets."

About Wisner Baum 

Wisner Baum is a nationally recognized plaintiffs' law firm with offices across the United States. For decades, the firm has represented individuals harmed by corporate misconduct, dangerous products, environmental exposure, and systemic failures. Wisner Baum is known for its trial experience, investigative rigor, and leadership in complex, high-impact litigation involving some of the world's largest companies. For more information, visit www.wisnerbaum.com 

References

1. Millstein, S. (2024, December 16). "How Revolving Door Politics Corrupt Food Systems." Sentient Media. https://sentientmedia.org/revolving-door-politics-food-system/
2. Office of U.S. Senator Jeff Merkley. (2026, March 26). "Sens. Schiff and Merkley Demand Extension of Ethics Guardrails on Trump EPA Chemical Appointees, End to Conflicts of Interest." https://www.merkley.senate.gov/sens-schiff-and-merkley-demand-extension-of-ethics-guardrails-on-trump-epa-chemical-appointees-end-to-conflicts-of-interest/
3. Bero, L., Anglemyer, A., Vesterinen, H., and Krauth, D. (2016). "The Relationship Between Study Sponsorship, Risks of Bias, and Research Outcomes in Atrazine Exposure Studies Conducted in Non-Human Animals: Systematic Review and Meta-Analysis." Environment International, 92–93, 597–604. https://doi.org/10.1016/j.envint.2015.10.011
4. Wisner Baum. (2019, August 15). "New Release of Monsanto Documents: Monsanto Papers Part III." https://www.wisnerbaum.com/blog/2019/august/new-release-of-monsanto-documents-monsanto-paper/
5. United States v. Keplinger, 776 F.2d 678 (7th Cir. 1985). https://law.justia.com/cases/federal/appellate-courts/F2/776/678/443220/
6. Williams, G. M., Kroes, R., and Munro, I. C. (2000). "RETRACTED: Safety Evaluation and Risk Assessment of the Herbicide Roundup and Its Active Ingredient, Glyphosate, for Humans." Regulatory Toxicology and Pharmacology, 31(2), 117–165. https://www.sciencedirect.com/science/article/pii/S0273230099913715
7. Internal Monsanto email concerning the planned Agency for Toxic Substances and Disease Registry glyphosate review. (2015, September 16). U.S. Right to Know document archive. https://usrtk.org/wp-content/uploads/2017/03/ificankillthis.pdf
8. Natural Resources Defense Council v. U.S. Environmental Protection Agency, 38 F.4th 34 (9th Cir. 2022). https://cdn.ca9.uscourts.gov/datastore/opinions/2022/06/17/20-70787.pdf
9. U.S. Environmental Protection Agency. (2026, May 5). "Glyphosate." https://www.epa.gov/ingredients-used-pesticide-products/glyphosate 
10. Monsanto Co. v. Durnell, 607 U.S. ___ (2026) (slip op. June 25, 2026). https://www.supremecourt.gov/opinions/25pdf/24-1068_n7ip.pdf 

Media Contact:

Karla Jo Helms
JOTO PR
727-777-4629
www.jotopr.com

SOURCE Wisner Baum

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Wisner Baum Named to Leadership in Federal Spinal Cord Stimulator Litigation

Wisner Baum Named to Leadership in Federal Spinal Cord Stimulator Litigation

Two Wisner Baum LLP attorneys have been appointed to leadership roles in the multidistrict litigation over Boston Scientific spinal cord stimulators, ...

Wisner Baum's Lawsuits Challenge FDA Oversight of Spinal Cord Implants

Wisner Baum's Lawsuits Challenge FDA Oversight of Spinal Cord Implants

National law firm Wisner Baum LLP recently filed lawsuits on behalf of patients across the United States alleging that spinal cord stimulator (SCS)...

More Releases From This Source

Explore

Chemical

Chemical

Chemical

Chemical

Environmental Products & Services

Environmental Products & Services

Agriculture

Agriculture

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content

About

  • About PR Newswire
  • About Cision
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.